🇺🇸 Moxifloxacin Hydrochloride, Ophthalmic in United States

16 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Eye Pain — 4 reports (25%)
  2. Eye Irritation — 2 reports (12.5%)
  3. Ocular Hyperaemia — 2 reports (12.5%)
  4. Product Quality Issue — 2 reports (12.5%)
  5. Chest Discomfort — 1 report (6.25%)
  6. Contraindicated Product Administered — 1 report (6.25%)
  7. Corneal Abrasion — 1 report (6.25%)
  8. Corneal Infection — 1 report (6.25%)
  9. Drug Administration Error — 1 report (6.25%)
  10. Dry Eye — 1 report (6.25%)

Source database →

Other Ophthalmology / Infectious Disease approved in United States

Frequently asked questions

Is Moxifloxacin Hydrochloride, Ophthalmic approved in United States?

Moxifloxacin Hydrochloride, Ophthalmic does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Moxifloxacin Hydrochloride, Ophthalmic in United States?

Laboratorios Sophia S.A de C.V. is the originator. The local marketing authorisation holder may differ — check the official source linked above.